The Juncker Plan’s European Fund for Strategic Investments (EFSI) has provided its backing to a European Investment Bank (EIB) loan worth €40 million to biotechnology company Nanobiotix.
The loan will help finance research and development by Nanobiotix of innovative cancer treatments. Commenting on the agreement, Commissioner Vytenis Andriukaitis said: “Cancer is the second-highest cause of death in the EU and with Europe’s ageing population, fighting cancer will undoubtedly remain a priority in the years to come. We need to have innovative and dedicated research to always be in search of new treatments. Nanoparticle based cancer treatment research funding is one example of how serious we are in fighting cancer, with the significant support from the EIB to finance research and innovation.” These latest loan agreements come following the confirmation that the Juncker Plan’s European Fund for Strategic Investments (EFSI) has mobilised €335 billion in additional investment across the EU since July 2015, exceeding the initial target of mobilising €315 billion of investment.
